RJA
IMGN

Raymond James & Associates’s Immunogen Inc IMGN Stock Holding History

Raymond James & Associates’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-104,485
Closed -$3.1M – 4084
2023
Q4 		$3.1M Sell
104,485
-63,093
-38% -$1.26M ﹤0.01% 1827
2023
Q3 		$2.66M Buy
167,578
+150,652
+890% +$2.51M ﹤0.01% 1842
2023
Q2 		$319K Sell
16,926
-28,482
-63% -$336K ﹤0.01% 3222
2023
Q1 		$174K Buy
45,408
+5,658
+14% +$24.1K ﹤0.01% 3527
2022
Q4 		$197K Sell
39,750
-170,987
-81% -$927K ﹤0.01% 3463
2022
Q3 		$1.01M Sell
210,737
-20,137
-9% -$106K ﹤0.01% 2381
2022
Q2 		$1.04M Sell
230,874
-11,066
-5% -$48.1K ﹤0.01% 2415
2022
Q1 		$1.15M Sell
241,940
-11,932
-5% -$66.1K ﹤0.01% 2493
2021
Q4 		$1.88M Sell
253,872
-5,395
-2% -$33.5K ﹤0.01% 2217
2021
Q3 		$1.47M Sell
259,267
-3,571
-1% -$20.6K ﹤0.01% 2318
2021
Q2 		$1.73M Sell
262,838
-5,951
-2% -$41.5K ﹤0.01% 2200
2021
Q1 		$2.18M Sell
268,789
-2,219
-0.8% -$18.1K ﹤0.01% 1954
2020
Q4 		$1.75M Sell
271,008
-19,449
-7% -$113K ﹤0.01% 1973
2020
Q3 		$1.05M Sell
290,457
-22,850
-7% -$92.3K ﹤0.01% 2152
2020
Q2 		$1.44M Buy
313,307
+16,081
+5% +$68.4K ﹤0.01% 1926
2020
Q1 		$1.01M Sell
297,226
-236,863
-44% -$1.04M ﹤0.01% 1967
2019
Q4 		$2.73M Sell
534,089
-49,346
-8% -$167K ﹤0.01% 1638
2019
Q3 		$1.41M Sell
583,435
-10,591
-2% -$28.1K ﹤0.01% 1975
2019
Q2 		$1.29M Sell
594,026
-25,297
-4% -$59.8K ﹤0.01% 2071
2019
Q1 		$1.68M Buy
619,323
+23,774
+4% +$103K ﹤0.01% 1876
2018
Q4 		$2.86M Sell
595,549
-53,284
-8% -$323K 0.01% 1422
2018
Q3 		$6.14M Buy
648,833
+75
+0% +$721 0.01% 1099
2018
Q2 		$6.31M Buy
648,758
+23,459
+4% +$247K 0.01% 1052
2018
Q1 		$6.58M Buy
625,299
+5,942
+1% +$58.7K 0.01% 992
2017
Q4 		$3.97M Buy
619,357
+161,603
+35% +$997K 0.01% 1255
2017
Q3 		$3.5M Sell
457,754
-90,163
-16% -$599K 0.01% 1273
2017
Q2 		$3.9M Sell
547,917
-80,319
-13% -$368K 0.01% 1153
2017
Q1 		$2.43M Sell
628,236
-13,924
-2% -$40.6K 0.01% 1414
2016
Q4 		$1.31M Sell
642,160
-15,042
-2% -$30.2K ﹤0.01% 1773
2016
Q3 		$1.76M Buy
657,202
+10,762
+2% +$31.3K ﹤0.01% 1539
2016
Q2 		$1.99M Buy
646,440
+19,016
+3% +$119K 0.01% 1333
2016
Q1 		$5.35M Buy
627,424
+12,063
+2% +$102K 0.02% 787
2015
Q4 		$8.35M Buy
615,361
+21,990
+4% +$271K 0.03% 592
2015
Q3 		$5.7M Buy
593,371
+29,856
+5% +$436K 0.02% 678
2015
Q2 		$8.1M Buy
563,515
+50,444
+10% +$554K 0.03% 598
2015
Q1 		$4.59M Buy
513,071
+99,093
+24% +$718K 0.02% 785
2014
Q4 		$2.52M Buy
413,978
+124,745
+43% +$1.14M 0.01% 1027
2014
Q3 		$3.06M Buy
289,233
+28,078
+11% +$318K 0.02% 867
2014
Q2 		$3.1M Buy
261,155
+38,916
+18% +$488K 0.02% 859
2014
Q1 		$3.32M Buy
222,239
+29,314
+15% +$462K 0.02% 753
2013
Q4 		$2.83M Buy
192,925
+27,912
+17% +$429K 0.02% 780
2013
Q3 		$2.81M Buy
165,013
+18,517
+13% +$325K 0.02% 714
2013
Q2 		$2.43M Buy
+146,496
New +$2.37M 0.02% 712

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Raymond James & Associates's IMGN Position: Q1 2024 in Review

Raymond James & Associates sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 104,485 shares — an estimated $3.1M sold.

Raymond James & Associates first reported a position in IMGN in Q2 2013 and held it in 43 quarters. The position peaked at $8.35M in Q4 2015. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • Raymond James & Associates reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • Raymond James & Associates sold 104,485 Immunogen Inc shares in Q1 2024, an estimated $3.1M.
  • Raymond James & Associates first reported a position in Immunogen Inc in Q2 2013 and held it in 43 quarters.
  • Raymond James & Associates's Immunogen Inc position peaked at $8.35M in Q4 2015.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.